IceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense® Cryoablation

Stock Information for IceCure Medical Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About IceCure Medical Ltd.

IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation
IceCure Reminds Shareholders of Upcoming Expiration of Rights Offering Subscription Period
IceCure Announces Commencement of Rights Offering
IceCure Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025
IceCure Announces Record Date for Rights Offering for Up to $10 Million
IceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient Outcomes
IceCure Medical Reports First Quarter 2025 Financial Results
IceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.